JAK inhibitors, such as tofacitinib, baricitinib, and ruxolitinib, selectively inhibit different JAK subtypes and effectively reduce the expression of various cytokines, such as IL-6, which plays a crucial role in sepsis and severe infections [127]. The gene discussed is IL6; the disease is infection.